Amneal Pharma up after US FDA approves sodium oxybate solution

Shares of drugmaker Amneal Pharmaceuticals AMRX.O rise 2% to $10.02

Company says the U.S. FDA has approved Amneal's sodium oxybate oral solution for the treatment of cataplexy or excessive daytime sleepiness in patients 7 years of age and older with narcolepsy

Amneal's solution is a generic version of Jazz Pharmaceuticals' JAZZ.O sleep disorder drug, Xyrem

Narcolepsy is a chronic neurological disorder that disrupts the body's ability to regulate sleep-wake cycles

Amneal says it had previously been distributing an authorized generic of sodium oxybate oral solution in limited quantities

Including session moves, stock up 25.6% YTD